Home
Programs
Center for Infectious Diseases
Division of Communicable Disease Control
COVID-19 Treatment Resources for Healthcare Providers

COVID-19 Treatment Resources for Healthcare Providers

October 2, 2024

Key point:

Effective outpatient treatment for patients with mild-to-moderate COVID-19 and at high risk for severe illness is available and should be offered to all eligible patients, with the primary goals of reducing hospitalizations and deaths.

Overview of COVID-19 Antivirals:

The following medications are FDA approved or under EUA for the outpatient treatment of COVID-19:

The following medications are FDA approved or under EUA for the pre-exposure prophylaxis (PReP) of COVID-19:

Pemgarda (pemivibart) (PDF)

Introduction:

COVID-19 treatments can help prevent severe illness in eligible patients.
Eligibility depends on exposure status, symptoms, and risk factors for severe disease. These risk factors include but are not limited to age over 50 years, being unvaccinated or not up to date on COVID-19 vaccinations, or having specific medical conditions.
CDPH recommends that providers prescribe nirmatrelvir/ritonavir (Paxlovid) to non-hospitalized, symptomatic, and eligible patients. Remdesivir (Veklury) should be considered when nirmatrelvir/ritonavir (Paxlovid) is clinically contraindicated, and molnupiravir (Lagevrio) may be considered if remdesivir is impractical and Paxlovid is clinically contraindicated.

Additional Resources: